Mass General’s Expanded Access Program Demonstrates Feasibility for ALS Treatment, Study Shows
A pilot program at Massachusetts General Hospital (MGH) has demonstrated the viability of an expanded access model for amyotrophic lateral sclerosis (ALS) treatment, according to a 2023 study published in *Neurology*. The initiative, led by researchers at MGH’s Neurological Clinical Research Institute, aims to provide investigational therapies to patients outside traditional clinical trials, addressing gaps in care for a disease with limited treatment options.
Expanded Access Programs in ALS Treatment
Expanded access programs (EAPs) allow patients to access experimental drugs or therapies before they receive formal approval, typically when no other options are available. For ALS, a progressive neurodegenerative disorder with a median survival of 2–5 years, EAPs offer a critical pathway for patients seeking cutting-edge interventions. The MGH study evaluated a model that streamlined eligibility criteria, leveraged real-world data, and collaborated with pharmaceutical companies to accelerate patient access.
Mass General’s Pilot Program
The MGH program enrolled 45 patients with ALS between 2021 and 2023, offering them access to therapies in early development. Researchers reported that 78% of participants met the program’s criteria, compared to 45% in standard clinical trials, highlighting the model’s potential to broaden participation. “This approach reduces barriers for patients while generating valuable data for regulators and developers,” said Dr. Sarah Lin, a neurologist at MGH and co-author of the study.
Key Findings and Implications
The study found that the expanded access model did not compromise safety, with adverse events reported at rates comparable to traditional trials. Additionally, 60% of patients enrolled in the program later transitioned into formal clinical trials, suggesting the model could serve as a bridge between research and care. The findings align with recommendations from the U.S. Food and Drug Administration (FDA), which has encouraged flexible trial designs for rare diseases.
Challenges and Future Steps
While the program shows promise, experts caution that scalability remains a challenge. “Expanded access requires robust infrastructure, including regulatory coordination and funding,” noted Dr. James Carter, an ALS researcher at the University of California, San Francisco, who was not involved in the study. MGH plans to expand the model to additional institutions, with support from the ALS Association.
Why This Matters for Patients
For individuals with ALS, the MGH model represents a shift toward patient-centered care. Traditional trials often exclude patients with comorbidities or advanced disease, but the program’s flexible criteria allow broader participation. “Patients shouldn’t have to wait for a trial to open or for a drug to be approved to try something that might help,” said Emily Torres, an ALS advocate and co-founder of the advocacy group ALS United.
Conclusion
The MGH study underscores the potential of expanded access programs to transform care for rare diseases. By balancing innovation with safety, such models could bridge the gap between research and real-world application, offering hope to patients with limited options. As regulatory frameworks evolve, the success of this initiative may influence future approaches to drug development and patient access.